(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 June 2013 (13.06.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/084151 A2

(51) International Patent Classification: Not classified

(21) International Application Number:
PCT/IB2012/056956

(22) International Filing Date:
4 December 2012 (04.12.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/566,912 5 December 2011 (05.12.2011) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors: **ELIS, Winfried**; Morphosys Ag, Lena-Christ-Strasse 48, 82152 Planegg (DE). **ETTENBERG, Seth**; Novartis Institutes For Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **GARNER, Andrew, Paul**; Novartis Institutes For Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **HAUBST, Nicole**; Morphosys Ag, Lena-Christ-Strasse 48, 82152 Planegg (DE). **HUET, Heather**; Novartis Institutes For Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **KUNZ, Christian, Carsten, Silvester**; Morphosys Ag, Lena-Christ-Strasse 48, 82152 Planegg (DE). **REISINGER SPRAGUE, Elizabeth, Anne**; Novartis Institutes For Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **SHENG, Qing**; Novartis Institutes For Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US).

(74) Agent: **SAGOO, Jasbir**; Novartis Pharma Ag, Patent Department, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,

[Continued on next page]

(54) Title: ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3) DIRECTED TO DOMAIN III AND DOMAIN IV OF HER3

(57) Abstract: The present invention relates to antibodies or fragments thereof that bind to a non-linear epitope within domain 3 of the HER3 receptor and inhibit both ligand-dependent and ligand-independent signal transduction. The invention also relates antibodies or fragments thereof that bind to amino acid residues within domains 3-4 of HER3 and inhibit both ligand-dependent and ligand-independent signal transduction; and compositions and methods of use of such antibodies or fragments thereof.




Figure 1

WO 2013/084151 A2

RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*